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THIS paper continues our studies (Marrian and Maxwell, 1956) of potential
radiosensitizers, compounds which, it is hoped, might selectively concentrate in
fast growing tissues and there accentuate the effects ofionising radiations. There
are good reasons for believing that tetrasodium 2-methyl-I: 4-naphthohydro-
quinone diphosphate (Synkavit) (I) can accumulate in tumour tissue for short
periods after intravenous injection (Mitchell, 1955; Marrian and Maxwell, 1956)
and we felt that related compounds carrying a y-emitting isotope might combine
radio-sensitization with, possibly, a useful dose of localised radiation. 82Br
and 1311 seemed the most useful isotopes for this purpose and this paper records
some observations on the metabolism of tetrasodium 2-methyl-3-82Br-bromo-I:
4-naphthohydroquinone diphosphate (II) and also of 2: 3-dimethyl-5: 6-di-1311-
iodo-I: 4-benzohydroquinone diphosphate (III). The antimitotic properties of
the former compound have been established (Friedmann, Marrian and Simon-
Reuss, 1952) and although the latter is inactive by the same test (Simon-Reuss,
unpublished) it seems to be one of the few hydroquinone diphosphates in which
labelling with 1311 is simple. Studies of its metabolism were therefore worth-
while, and served to confirm the lability ofhalogen in a substituted hydroquinone
ring.
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METHODS AND MATERIALS
Counting.-y-emission from the halogens was the basis of detection. The
simple technique ofplacing samples of the organs under a shielded counter could
not be used since variations in the thickness ofthe organs would vary the sample-
counter distance, leading to considerable counting errors. This type of error was
reduced by locating the sample on a thin aluminium tray midway between two
G-10-Pb glass-covered Geiger-Muller tubes in copper sheaths placed 10 cm.
apart in a castle of 2 inch lead and connected in parallel to the same scaler. The
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sensitivity of the arrangement was about 9000 c.p.m./,tC 52Br. Samples and
backgrounds were counted to a standard error of 5 per cent or less.
Solutionsfor injection
The synthesis of both compounds (II and III) has been reported (Andrews,
Marrian and Maxwell, 1956). The hydroscopic salt (II) was dissolved in 0 9 per
cent saline and the concentration determined by ultraviolet spectroscopy
(absorption maxima at 232m,u. (M = 70,000) and 290 m,u. (M = 5,800) in 0-01N-
hydrochloric acid). A solution of the compound ran as a single spot on paper
in saturated ammonium sulphate (80 vols.), 1 M-sodium acetate (20 vols.) and
iso-propanol (2 vols.). Both counting and autoradiography of the dried paper
strip showed that more than 95 per cent of the radioactivity was associated with
the ultraviolet absorbing spot and that less than 0* 6 per cent was present as
bromide ion, as detected by spraying the dried paper with a saturated solution of
fluoresceinin 50per cent ethanol and allowing to dry. Exposure to chlorine vapour
caused red spots of bromofluoroscein to appear on a yellow background. The
method is relatively insensitive, requiring about 100y of bromide for detection,
but it proved quite satisfactory for our requirements since as much carrier bromide
as necessary could be added before separating.
The iodinated compound (III), was dissolved in 0 9 per cent saline and
neutralised by addition ofsodium hydroxide solution. The purity ofthe solution
was determined by paper electrophoresis at pH 7 (Markham and Smith, 1952).
This clearly separated the organic compound from iodide ion, the former being
detected by ultraviolet photography and the latter by spraying with starch
solution and exposure to chlorine vapour. No detectable radioactivity was
associated with the area on the paper where carrier iodide appeared.
Ammonium 82Br-bromide was obtained by neutron irradiation of ammonium
bromide in the Harwell pile. It was dissolved in 0 9 per cent saline before
injection.
Attempted exchange reactions
Tetrasodium 2-methyl-3-bromo-1 4-naphthohydroquinone diphosphate and
ammonium82Br-bromide (9 moles excess)were incubatedat 70° C. for 4hours atpH
4, 6, 7 and 9 and the reaction mixtures examined by paper electrophoresis. No
exchange greater than 0 5 per cent (the lower limit of detection) had occurred.
When the reactants were present in molar ratio, the lower detection limit was 2-0
per cent but again no exchange could be detected.
Animal experiments
Rats carring a Walker carcinoma were used as previously described (Marrian
and Maxwell, 1956). Immediately after the compound had been injected, and
using the same syringe, aliquots of the dose were placed, in triplicate, on smaU
pieces of filter paper on aluminium planchettes. The radioactivity of these
planchettes when the organs were being counted was used to calculate the
differential absorption ratio (D.A.R.), (Marrian and Maxwell, 1956). In most
experiments with the bromo-compound, the time required to count the organ
necessitated a decay correction, calculated from the known half-life of
82Br-bromine (36 ± 0*2 hours).
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RESULTS
The efficiency ofthe double counter in reducing errors due to sample thickness
was deduced and confirmed as follows:
If Ao is the measured activity of a sample at distance d from a counter and
Ax is the activity of the same sample measured at distance x, then the error
introduced by this displacement is
E
A AO AO
By the inverse square law, it can be shown that when a single counter is used
the error is
E= 2x/d + 3(x/d)2
while if a sample is midway between two parallel counters, distance 2d apart,
the error is
E2= 3(x/d)2
This relation was verified by measuring the activity of a thin layer of silver 82Br-
bromide at various distances from the central tray with one and then both
counters in operation. The errors E1 and E2 were determined and the results
plotted in Fig. 1 which shows that the relations hold to a first approximation and
that the grror due to a sample thickness of 1*2 cm. would be 30 per cent using a
single counter and 5 per cent using a double counter.
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FIG. 1.-Reduction of the error in counting caused by varying sample thickness.
Upper curve: single counter. Lower curve: double counter.
Ordinate: Percentage error in the count.
Abscissa: Distance of the sample from the central plate in cm.
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Table I records the variation of D.A.R. with time in the organs of tumour-
bearing rats injected with 1 mg. (10.6 saC) of tetrasodium 2-methyl-3-82Br-bromo-
1: 4-naphthohydroquinone diphosphate. The small intestines and kidney had
an initial D.A.R. of about 1-5 which fell exponentially with time with a half-life
of about 30 hours; liver, spleen and muscle showed little variation with time,
the D.A.R. remaining between 0-5 and 1P0.
TABLE I.-Differential Absorption Ratios ± Standard Errors.
Time. 0*5 hours. 6 hours. 15 hours. 24 hours. 48 hours.
Tumour . . 21 -2 . 1-9 -3 .6± 1 . 1-5 ±-1 . -2
Muscle . . . 0-55±-1 . 0-6 -15 0-4±-02 . 0-3 -1 -
Testis . . . . 1-0 -2 . 1-2 +1 . 1-4±-2 . 0-9 -07 . 11± 3
Liver . . . . 0- . 0 9 1 . 0-6+ 03 . 04 06 . 0-6+15
Spleen . . . . 1-15±-05 . 0 9 -01 0-9±-01 . 0-75±-1 . 0-9+l
Kidney. . . . 1-450-1 . 1-25±*15 . 0-94.01 . 0-9 ±1 . 0 9±*3
Stomach + Contents 3-5 ±i3 4-7 ±-8 3-4± . 3-2 +-3 5 0± 7
Small intestine . . 145 01 . 11 * 1 . O9-4 -1 07 i*1
Brain . . . . 0-45± 04 . 05 ± -01 . 0-5 -03 . 0-4 -1 . 0-4+ 1
Percentage of injected dose
Blood . . . 14-0 . 12-4 . 12-1 . 90 . 6 6
Plasma. . . . 10-7 . 8-5 . 7-5 . 6-0 . 4-8
(10 hours)
Urine . . . . . 27 . 170 . 280 37 0
The radioactivity associated with the blood also fell exponentially from about
15 per cent of the injected dose after 30 minutes. The half-life was about 40
hours and plasma accounted for some 67 per cent ofthe radioactivity ofthe whole
blood.
The D.A.R. of the tumour was consistently higher than any of the above
organs and was only exceeded by that of the stomach and contents. The radio-
activity associated with the stomach, which will be discussed later in this paper,
was not investigated in our initial work with this compound, but the early
experiments serve to confirm the high tumour uptake compared with the other
organs listed. Fig. 2 typifies the results of 3 experiments; the experimental
points are where the lines change direction, each point being the mean determina-
tion on two rats. The individual determinations were within 5 per cent of the
mean. Removing as much ofthe blood as possible before dissection and counting
did not alter the general picture.
Radioactivity was slowly excreted in the urine, some 30-35 per cent of a 1
mg. (10-6,uC) dose appearing during 48 hours. Paper chromatography of samples
from a rat given 5 mg. (II) intravenously indicated that most ofthe radioactivity
was present as bromide ion. None of the injected compound could be detected
in urine collected from 2 to 6 hours after injection although small amounts wvere
present in that collected from 0 to 2 hours (Fig. 3).
The high radioactivity found in the stomach and contents (Table I) suggested
that here too, the radioactivity might be present as bromide ion, and this was
confirmed by paper electrophoresis of the stomach contents of a rat 6 hours
after injection of 10 mg. of the compound (Fig. 4).
The rapid liberation of bromide ion from compound (II) in vivo suggested that
the distribution found may have been typical ofinjected bromide ion rather than
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that of the substituted hydroquinone diphosphate. An experiment to determine
the distribution of intravenously injected ammonium 82Br-bromide (0.5 mg.)
was therefore carried out on 8 rats bearing a Walker carcinoma. This dose
contained the same amount of bromine as 2*5 mg. of 2-methyl-3-bromo-1: 4-
napthohydroquinone diphosphate. The results (Fig. 5) are in agreement with
those of other workers (Davenport and Fisher, 1940; Perlman, Morton and
Chaikoff, 1941) and show a general similarity to the distribution of radioactivity
observed after an injection of the radiobrominated diphosphate. This suggests
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FIG. 2.-Differential absorption ratios of the internal organs of the rat following intravenous
injection of 1 mg. (10-6 IAC) tetrasodium 2 - methyl - 3 - 82Br - bromo - 1: 4 - naphtho -
hydroquinone diphosphate:
1, tumour; 2, kidney; 3, testis; 4, liver; 5, brain; 6, lung.
Ordinate: Differential absorption rato.
Abscissa: Time in hours after injection.
that the early results shown in Fig. 2 and Table I refer to the distribution of
unchanged compound (II), while the later measurements will refer mainly to the
distribution of bromide ion.
The facile removal of bromide ion from compound (II) is unlikely to occur by
simple exchange since all attempts to affect the reaction in vitro were unsuccessful.
Although liver and thyroid have been shown to contain enzymes capable of
dehalogenating compounds related to thyroxine (Roche, Michel, Michel,
Gorbman and Lissitsky, 1953), it is more likely the dehalogenation ofcompound
(II) occurred by dephosphorylation and oxidation to 2-methy1-3-bromo-1:
4-naphthoquinone followed by reaction with, for example, sulphydryl material
(Andrews, Marrian and Maxwell, 1956).
The lability of halogen attached to a hydroquinone ring was also observed
with the iodinated compound (III). The D.A.R. of various tissues of a tumour
bearing rat at 0 5 and 3 hours after injection of 10 mg. (III) is shown in Table II.
The radioactivity ofthe thyroid is not given separately as it was found to contain
no more radioactivity than the surrounding tissue. Again, the D.A.R. of the
stomach was so high that dehalogenation was suspected and confirmed by paper
743D. H. MARRIAN AND D. R. MAXWELL
to
10300
0 5 JO 15
FiG. 3.-Radioactivity along a paper chromatogram of rat urine after injection of 5 mg.
of tetrasodium 2 - methyl - 3 -82Br - bromo - 1: 4 - naphthohydroquinone diphosphate,
showing positions occupied by bromide ion and by the injected compound (II).
Full curve: 0-2 hours.
Broken curve: 2-6 hours.
'Ordinate: Radioactivity in counts per minute.
Abscissa: Distance from starting line (arbitrary units).
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PIG. 4.-Paper electrophoresis ofstomach contents of a rat 6 hours after intravenous injection
of 10 mg. tetrasodium 2 - methyl - 3 -82Br - bromo - 1: 4 - naphthohydroquinone diphos-
phate showing position occupied by bromide ion.
Ordinate: Radioactivity in counts per minute.
Abscissa: Distance from starting line (arbitrary units).
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FIG. 5.-Differential absorption ratio of organs of the rat after intravenous injection of 0 5 mg.
(10 uC) of ammonium 82Br-bromide.
I, Stomach; 2, lung; 3, tumour; 4, kidney; 5, testis ;6, small intestine;
7, liver; 8, muscle.
Ordinate: Differential absorption ratio.
Abscissa: Time in hours after injection.
TABLE II.-Differential Absorption Ratios + Standard Errors
0 5 hours 3 hours
Tumour . . 11±02 0 7±01
Muscle . . 045±0-1 . 0 3±005
Testis . . 0 55 0*15 . 0*50±0*05
Liver . . 0 80j0*05 . 0*50±0*03
Spleen . . 0 85±0*05 . 040±0*05
Kidney . . 2 5±0 5 . 1 35±0*05
Stomach + contents . 8-5±1-0 8*0±0* 5
Percentage of Injected Dose
Blood . . . 11L010 5 0±0'5
Urine . . 17-0±3-0
electrophoresis both of the stomach contents and of urine collected during the
first 3 hours (Fig. 6 and 7).
From these data, we may conclude that the stomach contents and urine of
rats receiving the iodo compound (III) contain large amounts of iodide ion and
it is of interest to compare the resulting distribution with previous reports of the
study of injected iodide. In the mammalian body, the distribution of injected
iodide depends on the amount given. A high D.A.R. is shown by thyroid only
ifvery small amounts are administered, and high uptake is then also found in the
region of the pituitary (Phillips, 1955). The distrubution of larger doses is said
to resemble that of chloride (Wallace and Brodie, 1937), but unlike chloride, the
stomach concentrates iodide in the gastric juice relative to plasma (Leblond,
1948; Goldsmith, Stevens and Schiff, 1950). The distribution of 139y of
iodine in sodium 1311-iodide as reported by Stevens, Stewart, Quinlin and Meiken
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(1949) is very similar to the distribution shown in Table II, especially at the 0 5
hour period. This confirms that even half an hour after injection, much of the
label derived from compound (III) is present as free iodide ion; at this dose
0
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FIG. 6.-The distribution of radioactivity after paper electrophoresis of the contents of
stomach of a rat 3 hours after injection of 10 mg. 2: 3 - dimethyl - 5: 6 - dil3lI - iodobenzo-
hydroquinone diphosphate (III) showing the positions occupied by iodide ion and by the
injected compound.
Ordinate : Radioactivity ill counts per minute.
Abscissa: Distance from'starting line (arbitrary units).
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FIG. 7.-The distribution of radioactivity obtained on paper electrophoresis of rat urine
collected for 3 hours after injection of 10 mg. 2 : 3 - dimethyl - 5: 6 - dil3lI - iodo - 1: 4 -
benzohydroquinone diphosphate (III).
Ordinate: Radioactivity in counts per minute.
Abscissa: Distance from starting line (arbitrary units).
level (10 mg. (III) corresponding to 4 mg. iodine) thyroid would not be expected
to have a higher D.A.R. than the surrounding muscle.
The results of these studies indicate the limitations of labelling a potential
radiosensitizer of the hydroquinone diphosphate type with halogen in the
hydroquinone ring.
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SUMIMARY
1. The distribution ofradioactivity among the organs ofrats bearing a Walker
carcinomafollowinginjectionsof2-methyl-3-82Br-bromo-1:4-naphthohydroquinone
diphosphate, and of 2: 3-dimethyl-5: 6-di131I-iodo-i: 4-benzohydroquinone di-
phosphate has been studied.
2. Results show clearly that both compounds accumulate in tumour tissue
to a greater extent thaD in other organs or muscle, but that the halogen atoms
are quickly removed from the hydroquinone ring. Therefore, except for short
periods after injection, the distribution of radioactivity is that of bromide or
iodide ions respectively, with consequent high activity in the stomach contents.
3. The urine ofthe animals contains large amounts ofthe respective halide ion.
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